![sentrimed home slider with text 3 Creating Oral Precision Oncology Therapies by Targeting Podoplanin](https://sentrimed.com/wp-content/uploads/2024/01/sentrimed-home-slider-with-text-3.jpg)
News From Sentrimed
Sentrimed is an emerging biotech company developing novel, targeted therapies that exploit cell-to-cell communications essential to recognizing, immobilizing and eliminating abnormal cells. Our company is focused on:
![innovation icon Sentrimed innovation icon](https://sentrimed.com/wp-content/uploads/2024/04/innovation-icon-200x200.png)
INNOVATION
Unique, IP protected platform targeting novel validated pathways critical to cancer progression
![patient icon Sentrimed patient icon](https://sentrimed.com/wp-content/uploads/2024/04/patient-icon-200x200.png)
PATIENT-CENTRICITY
Biomarker driven, well-tolerated, oral medications focused on aggressive cancers with significant unmet needs
![enduring icon Sentrimed enduring icon](https://sentrimed.com/wp-content/uploads/2024/04/enduring-icon-200x200.png)
ENDURING IMPACT
Immobilize and eliminate tumor cells throughout the care continuum, alone or in combination with other agents